Price: $225.0
· 1 day: +14.21% · 5 days: +18.41% · 1 month: +65.92% · YTD: +662.97%
As of 2026-10-09 20:00 UTC.
52-week range: $22.28 – $225.0 (currently at 100% of the range).
The read
MRNA is in an uptrend, momentum soft. $250 is the level overhead; $200 the first support below.
5 of 6 technical checks lean bullish.
Price vs 50-day: above
Price vs 200-day: above
50d vs 200d avg: above
MACD: bearish
RSI momentum: 72
5-day tape: +18.4%
Trend
Uptrend · above 50-day & 200-day
Momentum
RSI 72.31 · neutral · MACD bearish
Trend strength
ADX 62.4 · strong trend
Location
+62.7% vs 50-day MA
52-week range
+0% from high · +906% from low
Volatility
ATR 16.08 · ~7.1%/day
Key levels
Level
Type
Distance
$250.0 (resistance)
round
11.11%
$275.0 (resistance)
round
22.22%
$200.0 (support)
round
-11.11%
$175.0 (support)
round
-22.22%
$138.26 (support)
sma 50
-38.55%
Indicators
RSI (14)
72.31
MACD
18.9867
ADX (14)
62.4
ATR (14)
16.08
50-day average
$138.26
200-day average
$72.63
Next earnings: 2026-11-05.
Latest MRNA news
Spike in Interest Rates Is Doing Plenty of Damage to Stocks — Rising interest rates are exerting significant downward pressure on stock markets, as evidenced by a spike in the US 10-year Treasury yield to 5.23%, which is dampening equity valuations. Brent crude oil futures fell 2.9 (Bloomberg Business, 2026-10-02)
Moderna Tumbles as Citi Advises Selling Following 600% Rally — Moderna Inc. shares experienced their largest single-day decline in a month after Citigroup issued a sell recommendation, citing the stock's valuation as 'unjustifiable' following a nearly 600% rally this year. The analy (Bloomberg Business, 2026-09-30)
Citi tells investors it's time to sell Moderna after 600%-plus stock gains — Citi downgraded Moderna's stock to sell from hold, citing unrealistic sales assumptions despite a 600%-plus rally this year. The firm raised its price target to $80 from $60, still far below the stock's Tuesday close of (Morningstar, 2026-09-30)
Moderna has been on a tear since mid-August. Citi now sees it plunging 60% — Citi downgraded Moderna to sell, raising its price target to $80 from $60, implying roughly 60% downside from Tuesday's close of $203.46. Analyst Geoff Meacham cited unsustainable valuation levels after shares rallied 22 (CNBC, 2026-09-30)
Weekly Market Update: Stocks Gain 1.09% as Technology Rises, Energy Falls — # Summary
The Morningstar US Total Market Index rose 1.09% for the week ended September 25, driven by strong performance in technology (up 3.1%) and healthcare (up 1.57%) sectors, while energy and utilities declined 3.0 (Morningstar, 2026-09-25)